|Articles|August 12, 2016

New CEO for Israel's BioLineRx

August 12, 2016

Tel Aviv, Israel-based BioLineRx Ltd. announced that Philip A. Serlin has been named Chief Executive Officer, effective October 10, 2016. Mr. Serlin joined the company in 2009 as Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who has served as CEO since 2010. Dr. Savitsky will serve as scientific advisor to the Company through the end of March 2017.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

New CEO for Israel's BioLineRx

Related Content

“AI as Reinvention”: Transforming the Business of Medicine

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

Insilico Announces Collaboration with SK Biopharmaceutical for AI-Powered CNS Treatment

Additive Manufacturing's Application in Pharma and Biotech

Expanding the Vaccine Landscape with New Technologies: Q&A with Silvia Taylor

Trending on PharmExec

The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market

Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion

Catalent Announces Expanded Partnership with Nanoscope Therapeutics

Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last

Pharmaceutical Executive Daily: The Changing Reality of Pharmaceutical Commercialization